People_

Dr Tania Moujaber

Clinical Senior Lecturer
Westmead Clinical School/Faculty of Medicine and Health(FMH)

Email

tania.moujaber@sydney.edu.au

Publications

By Type

Expand all

Journals

Hamid, M., Hayden, A., Moujaber, T., Turner, S., Gurney, H., Grossmann, M., Wong, P. (2023). Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy. Medical Journal of Australia, 218(3), 126-130. [More Information]
Brown, L., Esteves Domingues Pires da Silva, I., Moujaber, T., Gao, B., Hui, R., Gurney, H., Carlino, M., Nagrial, A. (2023). Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Medicine, 12(6), 6788-6801. [More Information]
Moujaber, T., Balleine, R., Gao, B., Barner Madsen, I., Harnett, P., deFazio, A. (2022). New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer, 29(1), R1-R16. [More Information]
Shek, D., Akhuba, L., Carlino, M., Nagrial, A., Moujaber, T., Read, S., Gao, B., Ahlenstiel, G. (2021). Immune-checkpoint inhibitors for metastatic colorectal cancer: A systematic review of clinical outcomes. Cancers, 13(17), 4345. [More Information]
Tang, M., O'Connell, R., Amant, F., Beale, P., McNally, O., Sjoquist, K., Grant, P., Davis, A., Sykes, P., Mileshkin, L., Moujaber, T., Kennedy, C., deFazio, A., et al (2019). PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 154(3), 531-538. [More Information]
Moujaber, T., Etemadmoghadam, D., Kennedy, C., Chiew, Y., Balleine, R., Saunders, C., Wain, G., Gao, B., Hogg, R., Srirangan, S., Harnett, P., deFazio, A., et al (2018). BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2, 1-14. [More Information]
Etemadmoghadam, D., Azar, W., Lei, Y., Moujaber, T., Garsed, D., Kennedy, C., Fereday, S., Mitchell, C., Chiew, Y., Hendley, J., Sharma, R., Harnett, P., deFazio, A., et al (2017). EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas. Cancer Research, 77(16), 4268-4278. [More Information]
Janssen, A., Shaw, T., Bradbury, L., Moujaber, T., NÃ¸rrelykke, A., Zerillo, J., LaCasce, A., Co, J., Robinson, T., Starr, A., et al (2016). A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. BMC Medical Education, 16, 1-9. [More Information]
Moujaber, T., MacIntyre, C., Backhouse, J., Gidding, H., Quinn, H., Gilbert, G. (2008). The seroepidemiology of Helicobacter pylori infection in Australia. International Journal of Infectious Diseases, 12(5), 500-504. [More Information]

show 6 more

By Year

Expand all

2023

Hamid, M., Hayden, A., Moujaber, T., Turner, S., Gurney, H., Grossmann, M., Wong, P. (2023). Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy. Medical Journal of Australia, 218(3), 126-130. [More Information]
Brown, L., Esteves Domingues Pires da Silva, I., Moujaber, T., Gao, B., Hui, R., Gurney, H., Carlino, M., Nagrial, A. (2023). Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Medicine, 12(6), 6788-6801. [More Information]

2022

Moujaber, T., Balleine, R., Gao, B., Barner Madsen, I., Harnett, P., deFazio, A. (2022). New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer, 29(1), R1-R16. [More Information]

2021

Shek, D., Akhuba, L., Carlino, M., Nagrial, A., Moujaber, T., Read, S., Gao, B., Ahlenstiel, G. (2021). Immune-checkpoint inhibitors for metastatic colorectal cancer: A systematic review of clinical outcomes. Cancers, 13(17), 4345. [More Information]

2019

Tang, M., O'Connell, R., Amant, F., Beale, P., McNally, O., Sjoquist, K., Grant, P., Davis, A., Sykes, P., Mileshkin, L., Moujaber, T., Kennedy, C., deFazio, A., et al (2019). PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 154(3), 531-538. [More Information]

2018

Moujaber, T., Etemadmoghadam, D., Kennedy, C., Chiew, Y., Balleine, R., Saunders, C., Wain, G., Gao, B., Hogg, R., Srirangan, S., Harnett, P., deFazio, A., et al (2018). BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2, 1-14. [More Information]

2017

Etemadmoghadam, D., Azar, W., Lei, Y., Moujaber, T., Garsed, D., Kennedy, C., Fereday, S., Mitchell, C., Chiew, Y., Hendley, J., Sharma, R., Harnett, P., deFazio, A., et al (2017). EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas. Cancer Research, 77(16), 4268-4278. [More Information]

2016

Janssen, A., Shaw, T., Bradbury, L., Moujaber, T., NÃ¸rrelykke, A., Zerillo, J., LaCasce, A., Co, J., Robinson, T., Starr, A., et al (2016). A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. BMC Medical Education, 16, 1-9. [More Information]

2008

Moujaber, T., MacIntyre, C., Backhouse, J., Gidding, H., Quinn, H., Gilbert, G. (2008). The seroepidemiology of Helicobacter pylori infection in Australia. International Journal of Infectious Diseases, 12(5), 500-504. [More Information]

Selected Grants

2023